Fiche centre
Novartis Investigative Site
Rennes — France
Essais liés3clinical trials
VilleRenneslocalisation
PaysFrancelocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07225504
Essais cliniques associés
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| rapcabtagene autoleucel (YTB323) | SEP | Phase 1/2 | NCT06675864 | Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS) | ACTIVE_NOT_RECRUITING |
| Remibrutinib (Blinded) | SEP | Phase 3 | NCT07225504 | REMASTER — A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis | RECRUITING |
| rapcabtagene autoleucel (YTB323) | SEP | Phase 1/2 | NCT06617793 | An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING |